-
公开(公告)号：US10921311B2
公开(公告)日：2021-02-16
申请号：US16070110
申请日：2017-01-13
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Kengo Takeuchi , Seiji Sakata , Yuki Togashi , Naoya Fujita , Ryohei Katayama
IPC: C07H21/04 , C12Q1/68 , G01N33/50 , C12N9/12 , G01N33/574 , C12N9/88 , C07K14/82 , A61K31/519 , A61P35/00 , A61K38/00 , C12N15/113 , C12N15/62 , C12Q1/6886 , C12Q1/6853 , C12Q1/686
Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.
-
公开(公告)号：US20150185223A1
公开(公告)日：2015-07-02
申请号：US14417474
申请日：2013-07-26
Applicant: The University of Tokyo , Japanese Foundation for Cancer Research , Educational Foundation Jichi Medical University
Inventor： Hiroyuki Mano , Masahito Kawazu , Kengo Takeuchi , Yoshio Miki , Toshihide Ueno
IPC: G01N33/574 , C12N15/113 , C12Q1/68 , A61K31/7088 , C12N9/14 , C07K16/40 , A61K45/06
CPC classification number: G01N33/57496 , A61K31/7088 , A61K45/06 , C07K14/82 , C07K16/40 , C12N9/14 , C12N15/1137 , C12N2310/14 , C12N2320/31 , C12Q1/6886 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , C12Y306/05002 , G01N33/57407 , G01N2333/914
Abstract: The present invention is based, in part, on the discovery of isolated nucleic acid molecules encoding mutant RAC polypeptides, or fragments thereof, wherein the mutant RAC polypeptides comprise one or more substitutions of an amino acid in the wild-type RAC polypeptide that renders the mutant RAC polypeptides constitutively active and oncogenic. Isolated mutant RAC polypeptides encoded by such nucleic acid molecules, as well as vectors, host cells, methods of producing encoded polypeptides using such isolated nucleic acid molecules, as well as methods of using mutant RAC nucleic acids and polypeptides for identifying, assessing, prognosing, and treating cancer, are also provided.
Abstract translation: 本发明部分地基于编码突变体RAC多肽或其片段的分离的核酸分子的发现，其中突变体RAC多肽包含野生型RAC多肽中氨基酸的一个或多个取代，其使得 突变体RAC多肽组成型活性和致癌性。 由这种核酸分子编码的分离的突变体RAC多肽以及载体，宿主细胞，使用这种分离的核酸分子产生编码的多肽的方法，以及使用突变体RAC核酸和多肽来鉴定，评估， 并提供治疗癌症。
-
3.发明公开公开(公告)号：US20230323475A1
公开(公告)日：2023-10-12
申请号：US18314267
申请日：2023-05-09
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Kengo Takeuchi , Kana Sakamoto , Ryohei Katayama , Seiji Sakata
IPC: C12Q1/6886 , A61K31/167 , G01N33/50 , G01N33/48 , A61K31/551 , G01N33/574 , A61K31/4745 , A61K45/00 , C12Q1/68 , A61P35/02 , A61P43/00 , A61K31/4045 , A61K31/55 , A61K31/635 , A61K31/675
CPC classification number: C12Q1/6886 , A61K31/167 , G01N33/5023 , G01N33/48 , G01N33/5011 , G01N33/5047 , A61K31/551 , G01N33/57426 , A61K31/4745 , A61K45/00 , G01N33/5748 , C12Q1/68 , A61P35/02 , A61P43/00 , A61K31/4045 , A61K31/55 , A61K31/635 , A61K31/675 , G01N2333/82 , C12Q2600/158 , G01N2800/56 , C12Q2600/16
Abstract: The diagnostic markers that provide novel diagnostic criteria to blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been searched, and the presence of immunoblastoid cytomorphology, 8q24 rearrangement, and MYC expression were established as novel markers for subtyping BPDCN. It has been further found that the inhibitors which directly or indirectly inhibit the expression, functions, or signaling pathways of MYC, such as BET bromodomain-selective inhibitors or aurora kinase inhibitors, are effective in MYC-positive BPDCN, and HDAC inhibitors or BCL2 family protein inhibitors are effective as therapeutic drugs for BPDCN.
-
公开(公告)号：US20220384037A1
公开(公告)日：2022-12-01
申请号：US17639062
申请日：2020-08-27
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH , KONINKLIJKE PHILIPS N.V. , FINGGAL LINK CO., LTD.
Inventor： Naoko Tsuyama , Kengo Takeuchi , Sayuri Nakamura , Masayuki Hayashi , Takuya Sato
Abstract: A laboratory information system (LIS) is linked with a whole slide image (WSI) management system to build a pathology image management system that can efficiently manage and utilize a digitized pathology image. A scan notification notifying that an image of a glass slide is scanned by a scanner is delivered to the LIS from the WSI management system to form a WSI link in the LIS, so that the LIS is linked with the WSI management system. By linking two systems with each other can eliminate the problem of mixing up specimens, for example, and hence, a pathologist can easily grasp the status of a pathology sample for which the pathologist is responsible.
-
公开(公告)号：US20190033293A1
公开(公告)日：2019-01-31
申请号：US16070110
申请日：2017-01-13
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Kengo Takeuchi , Seiji Sakata , Yuki Togashi , Naoya Fujita , Ryohei Katayama
Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.
-
Patent Agency Ranking
公开(公告)号：US12198811B2
公开(公告)日：2025-01-14
申请号：US17639062
申请日：2020-08-27
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH , KONINKLIJKE PHILIPS N.V. , FINGGAL LINK CO., LTD.
Inventor： Naoko Tsuyama , Kengo Takeuchi , Sayuri Nakamura , Masayuki Hayashi , Takuya Sato
Abstract: A laboratory information system (LIS) is linked with a whole slide image (WSI) management system to build a pathology image management system that can efficiently manage and utilize a digitized pathology image. A scan notification notifying that an image of a glass slide is scanned by a scanner is delivered to the LIS from the WSI management system to form a WSI link in the LIS, so that the LIS is linked with the WSI management system. By linking two systems with each other can eliminate the problem of mixing up specimens, for example, and hence, a pathologist can easily grasp the status of a pathology sample for which the pathologist is responsible.
-
公开(公告)号：US12055538B2
公开(公告)日：2024-08-06
申请号：US17144776
申请日：2021-01-08
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Kengo Takeuchi , Seiji Sakata , Yuki Togashi , Naoya Fujita , Ryohei Katayama
IPC: C07H21/04 , A61K31/519 , A61K38/00 , A61P35/00 , C07K14/82 , C12N9/12 , C12N9/88 , C12N15/113 , C12N15/62 , G01N33/50 , G01N33/574 , C12Q1/6853 , C12Q1/686 , C12Q1/6886
CPC classification number: G01N33/5011 , A61K31/519 , A61K38/005 , A61P35/00 , C07K14/82 , C12N9/12 , C12N9/88 , C12N15/113 , C12N15/62 , C12Y207/11025 , C12Y402/01047 , G01N33/57446 , C12Q1/6853 , C12Q1/686 , C12Q1/6886
Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.
-
公开(公告)号：US20210140943A1
公开(公告)日：2021-05-13
申请号：US17144776
申请日：2021-01-08
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Kengo Takeuchi , Seiji Sakata , Yuki Togashi , Naoya Fujita , Ryohei Katayama
IPC: G01N33/50 , C12N9/12 , G01N33/574 , C12N9/88 , C07K14/82 , A61K31/519 , A61P35/00 , A61K38/00 , C12N15/113 , C12N15/62
Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.
-
公开(公告)号：US10705087B2
公开(公告)日：2020-07-07
申请号：US14907689
申请日：2014-07-25
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Kengo Takeuchi , Yuki Togashi , Seiji Sakata , Satoko Baba
IPC: C12Q1/68 , G01N33/574 , C12Q1/6886 , G01N33/50 , A61K31/277 , A61K31/553
Abstract: A polynucleotide, which is a novel causative gene for cancer, is elucidated, and, based on this finding, provided are a method for detecting the polynucleotide, or a polypeptide encoded by the polynucleotide; a kit and a primer set for the detection; a method for screening an inhibitor of the polypeptide; and a pharmaceutical composition for treating a cancer containing the inhibitor. In the detection method of the present invention, an NTRK3 fusion protein, or a fusion gene encoding the fusion protein, or an ETV6 fusion protein, or a fusion gene encoding the fusion protein, in a sample derived from the digestive system obtained from a subject, is detected.
-
10.发明授权公开(公告)号：US10585100B2
公开(公告)日：2020-03-10
申请号：US15569898
申请日：2016-04-28
Applicant: KYOTO UNIVERSITY , JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Seishi Ogawa , Keisuke Kataoka , Kengo Takeuchi
IPC: G01N33/574 , A61K39/395 , C12Q1/68 , C12N15/09 , A61K45/00 , C07K16/28 , C07K16/18
Abstract: An object of the present invention is to provide an effective method of predicting an effect of treatment by a PD-1/PD-L1 blockade, which is a method of predicting whether or not PD-1/PD-L1 blockade is effective for treatment of a subject suffering from a malignant tumor, which comprises detecting abnormality of genome relating to effectiveness of the PD-1/PD-L1 blockade in a tumor cell taken from the subject and evaluating the PD-1/PD-L1 blockade as useful for the treatment of the subject when there is the abnormality.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.016 seconds)
